Lumida
/GKOS
⌘K
Glaukos Corp

Glaukos Corp

GKOS
$156.83USD↑+0.93%+1.44 today

MARKET CAP

9.2B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$152 – $158

52W RANGE

$73
$162

AI Summary

Stalk
Buy NowMedium

GKOS is in a Stage 2 advance, led by a dominant Lockout Rally driving forced participation and rapid upside repricing. The medium-term bias remains bullish, underpinned by clear higher highs and higher lows and rising EMAs. Short-term execution is enabled by the Lockout Rally override, allowing participation despite overbought readings, with price holding tightly above the 9/21 EMA zone.

  • ↑Q1 revenue was $150.6M (+41% YoY); glaucoma franchise sales rose 58%.
  • ↑CEO cites strong execution; gross margin at 84% reflects efficiency.
  • ↓Q1 net loss of $0.18/share underscores ongoing unprofitability.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Glaukos Corporation (NASDAQ: GKOS) is a leading innovator in the ophthalmology sector, specializing in advanced surgical and pharmaceutical treatments for chronic eye diseases, particularly glaucoma. The company is focused on pioneering therapeutic solutions that redefine treatment paradigms, notably through its iDose-TR and Epioxa products. Positioned favorably in the growing ophthalmic market, Glaukos is capitalizing on the increasing demand for interventional solutions, especially as it addresses unmet needs in conditions like keratoconus.

Bull says

  • ↑Q1 revenue was $150.6M (+41% YoY); glaucoma franchise sales rose 58%.
  • ↑CEO cites strong execution; gross margin at 84% reflects efficiency.
  • ↑FDA approved Epioxa for keratoconus covering 100M lives; early sales $17.7M.
  • ↑Needham maintains Buy rating and raised price target to $150.
  • ↑Full-year guidance lifted to $620–635M in net sales.
  • ↑Robust growth momentum and qualitative factors support upside.

Bear says

  • ↓Q1 net loss of $0.18/share underscores ongoing unprofitability.
  • ↓Epioxa transition may face reimbursement delays after Fortrexa decline.
  • ↓Intensifying international competition risks market share erosion.
  • ↓Operating expenses set to grow mid-teens %, pressuring cash flow.
  • ↓High leverage and weak profitability raise financing concerns.
  • ↓Soft momentum factors could deter investors amid market uncertainty.

Investment themes with GKOS

Medical Devices↑ +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK
Demographics: Elderly Care↓ -0.26%

Services and products for aging population

UCB.BR · JNJ · AZN

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-01-2026neutral

Transcript signals

Bull points

  • we continue to add customers and drive that forward
  • We'll monitor those patients over the course of this year. We plan to file by the end of this year, and we expect to be in position for targeted approval in the fourth quarter of 2027.
  • a lot of that spend is going, it shouldn't surprise you, it's much more in that initial lift confidence and process associated with claims prosecution and adjudication. It's about making sure that customers understand how it works, that they're successfully seeking prior authorizations,

Bear points

  • there are certainly some markets internationally that can support the type of therapies that we're talking about with Epioxa and with IDOS
  • physicians are still pushing back or are pushing back on the price tag of Eidos.
  • about 50% of those patients are in plans where there's a specific policy attached to it, and the remainder where there's silence,
Read full transcript analysis ›